Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy
Year: 2015
Type: article
Abstract: This commentary argues that while cutaneous adverse effects are associated with better outcomes among patients undergoing treatment with pembrolizumab, further analysis is required to determine whether nonvitiligo cutaneous adverse effects contribute to the observed outcome.
Source: JAMA Oncology
Institution: Massachusetts General Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1913801405